Adamax

Research Overview

Adamax serves as a valuable research tool for investigating neuroprotective mechanisms, microtubule stabilization, and cognitive preservation in laboratory settings. This synthetic octapeptide was identified through structure-activity relationship studies of activity-dependent neuroprotective protein (ADNP), a vasoactive intestinal peptide (VIP)-responsive gene product critical for brain development and function. VIP-related neuropeptide research intersects with studies using Pinealon, a pineal-derived bioregulatory tripeptide targeting neuroprotective gene expression. Research applications focus on understanding Adamax’s unique neuroprotective mechanisms distinct from classical neurotrophic factors. Cognitive enhancement research employs multiple peptide tools including Noopept for glutamatergic synaptic plasticity studies and Selank for GABAergic anxiolytic mechanisms, providing distinct pharmacological approaches to neurological research.

The peptide’s development stemmed from investigations into ADNP’s protective functions during neural development and stress responses. ADNP-deficient animal models demonstrate severe developmental abnormalities and cognitive impairment, establishing ADNP’s essential role in brain formation and function. Adamax (NAP) was identified as the smallest active fragment maintaining ADNP’s neuroprotective activity, providing researchers with a tractable tool for mechanistic investigation.

Laboratory studies investigate Adamax’s effects on neuronal survival, neurite outgrowth, synaptic maintenance, and cognitive function markers in preclinical models. Research demonstrates the peptide’s ability to protect neurons against diverse insults including oxidative stress, excitotoxicity, protein aggregation, and inflammatory challenges. These broad protective effects make Adamax valuable for investigating common neuroprotective pathways across neurodegenerative conditions.

Molecular Characteristics

Complete Specifications:

• Chemical Name: Adamax, NAP, AL-108, Davunetide
• Molecular Weight: 910.03 Da
• Molecular Formula: C₃₇H₆₆N₁₀O₁₅
• Amino Acid Sequence: Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (NAPVSIPQ)
• Parent Protein: Activity-Dependent Neuroprotective Protein (ADNP)
• Peptide Classification: Neuroprotective octapeptide
• Appearance: White to off-white lyophilized powder
• Solubility: Water, bacteriostatic water, phosphate buffered saline
• Net Charge: Neutral at physiological pH

The peptide’s 8-amino acid structure incorporates the essential neuroprotective core of ADNP. Two proline residues (positions 3 and 7) contribute to conformational properties important for biological activity. The sequence includes hydrophobic residues (valine, isoleucine) and polar residues (asparagine, serine, glutamine) creating amphipathic character potentially relevant for protein-protein interactions. The N-terminal asparagine and C-terminal glutamine are critical for activity, as modifications to these residues significantly reduce neuroprotective efficacy in research models.

Pharmacokinetic Profile in Research Models

Adamax pharmacokinetic characterization in preclinical research reveals important properties for experimental design:

Absorption and Distribution:

• Intranasal bioavailability: Documented CNS penetration in rodent models
• Blood-brain barrier penetration: Confirmed through various administration routes
• Peak brain concentrations: 30-60 minutes post-intranasal administration
• Regional distribution: Widespread CNS distribution with accumulation in vulnerable brain regions
• Peripheral tissue distribution: Detected in liver, kidney, and other organs

Metabolism and Elimination:

• Plasma half-life: Approximately 1-2 hours following systemic administration
• Metabolic stability: Moderate peptidase resistance, C-terminal amidation enhances stability
• Primary metabolism: Enzymatic cleavage at specific peptide bonds
• Biological effects: Sustained beyond plasma detection through protein binding and cellular internalization
• Elimination route: Renal clearance of peptide and metabolites

Pharmacodynamic Considerations:

• Rapid cellular uptake documented in neuronal cultures
• Intracellular localization: Cytoplasmic and associated with microtubule structures
• Duration of neuroprotection: Hours to days depending on injury model and administration
• Cumulative effects: Repeated administration enhances neuroprotective outcomes

These pharmacokinetic characteristics inform research protocol design, particularly regarding intranasal delivery for CNS research, administration frequency, and timing of outcome assessments in experimental models.

Research Applications

Microtubule Stabilization Research

Adamax serves as a research tool for investigating microtubule dynamics and stabilization mechanisms:

• Tubulin Interaction Studies: Investigation of direct or indirect interactions with α/β-tubulin
• Microtubule Assembly Research: Analysis of tubulin polymerization and microtubule formation enhancement
• Microtubule-Associated Protein Modulation: Studies on MAP2, tau, and other MAP interactions
• Axonal Transport Research: Investigation of cargo transport along microtubules and motor protein function
• Microtubule Dynamics Analysis: Research on microtubule stability, catastrophe, and rescue events

Research protocols employ cell-free tubulin polymerization assays, live-cell imaging of microtubule dynamics, immunofluorescence analysis of microtubule networks, and axonal transport assays to characterize Adamax’s microtubule-related effects.

Tau Protein and Tauopathy Research

Laboratory studies investigate Adamax in tau-related research applications:

• Tau Phosphorylation Studies: Analysis of tau hyperphosphorylation modulation and kinase/phosphatase balance
• Tau Aggregation Research: Investigation of paired helical filament formation and neurofibrillary tangle prevention
• Tau-Microtubule Binding: Studies on tau-microtubule interaction enhancement and microtubule stabilization
• Tau Pathology Models: Research in cellular and animal models of tauopathy and Alzheimer’s disease
• Tau Clearance Mechanisms: Investigation of tau degradation and autophagy pathway modulation

Experimental models include tau-overexpressing cell lines, tau transgenic animal models, and post-mortem tissue analysis to evaluate Adamax’s effects on tau pathology and related cognitive deficits.

Neuroprotection Mechanism Studies

Adamax facilitates investigation of neuroprotective mechanisms against diverse insults:

• Oxidative Stress Protection: Research on ROS modulation, antioxidant enzyme expression, and oxidative damage prevention
• Excitotoxicity Studies: Investigation of glutamate-induced neurotoxicity protection and calcium homeostasis
• Apoptosis Pathway Research: Analysis of cell death signaling, caspase activation, and survival pathway enhancement
• Protein Aggregation Models: Studies on protection against β-amyloid, α-synuclein, and other toxic protein aggregates
• Inflammatory Modulation: Investigation of neuroinflammation, microglial activation, and cytokine profile effects

Laboratory protocols employ diverse injury models in primary neuronal cultures, organotypic brain slices, and in vivo injury models to characterize Adamax’s broad neuroprotective spectrum.

Cognitive Function Research

Research applications extend to cognitive enhancement and preservation studies:

• Memory Formation Research: Investigation of learning, consolidation, and retrieval processes
• Spatial Cognition Studies: Analysis using Morris water maze, Barnes maze, and radial arm maze paradigms
• Recognition Memory: Research employing novel object recognition and object location tasks
• Cognitive Aging Models: Studies on age-related cognitive decline prevention and reversal
• Neurodegenerative Cognition: Investigation in Alzheimer’s, Parkinson’s, and other neurodegenerative models

Experimental protocols correlate Adamax’s molecular effects (microtubule stabilization, neuroprotection, synaptic preservation) with cognitive performance outcomes across diverse behavioral paradigms.

Neurodevelopmental Research Applications

Adamax’s derivation from developmentally essential ADNP enables neurodevelopmental investigations:

• Neural Differentiation Studies: Research on neuronal precursor differentiation and maturation
• Neurite Outgrowth Research: Investigation of axon and dendrite extension, branching, and pathfinding
• Synaptic Development: Studies on synaptogenesis, synaptic pruning, and circuit formation
• Neural Migration Research: Analysis of neuronal migration during brain development
• ADNP Function Investigation: Studies using ADNP deficiency models to understand protein function

Research protocols examine Adamax’s ability to rescue developmental deficits in ADNP-deficient models and its effects on normal developmental processes in cultured neurons and developing brain preparations.

Neurodegenerative Disease Model Research

Laboratory studies investigate Adamax across multiple neurodegenerative disease models:

• Alzheimer’s Disease Models: Research in APP/PS1, 3xTg-AD, and other Alzheimer’s transgenic models
• Parkinson’s Disease Research: Studies in MPTP, 6-OHDA, and α-synuclein models
• Amyotrophic Lateral Sclerosis: Investigation in SOD1 and TDP-43 ALS models
• Huntington’s Disease Research: Studies in mHtt transgenic models
• Traumatic Brain Injury: Research in controlled cortical impact and fluid percussion injury models

Experimental approaches examine Adamax’s effects on pathological protein accumulation, neuronal loss, neuroinflammation, and functional deficits across these diverse neurodegenerative conditions.

Laboratory Handling and Storage Protocols

Lyophilized Powder Storage:

• Store at -20°C to -80°C in original sealed vial
• Protect from light exposure and moisture
• Desiccated storage environment required
• Stability data available for 12+ months at -20°C

Stability Considerations:
Adamax demonstrates moderate stability in solution. C-terminal amidation (when present in specific formulations) enhances metabolic stability. Standard peptide handling protocols should be followed to maintain biological activity throughout experimental procedures.

Quality Assurance and Analytical Testing

Each Adamax batch undergoes comprehensive analytical characterization:

Purity Analysis:

• High-Performance Liquid Chromatography (HPLC): ≥98% purity
• Analytical method: Reversed-phase HPLC with UV detection at 215nm
• Multiple peak integration to ensure accurate purity determination

Structural Verification:

• Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms molecular weight 910.03 Da
• Amino acid analysis: Verifies sequence composition
• Peptide content determination: Quantifies actual peptide content by weight
• N-terminal and C-terminal sequencing: Confirms sequence integrity

Contaminant Testing:

• Bacterial endotoxin: <5 EU/mg (LAL method)
• Heavy metals: Below detection limits per USP standards
• Residual solvents: TFA and acetonitrile within acceptable limits
• Water content: Karl Fischer titration (<8%)

Documentation:

• Certificate of Analysis (COA) provided with each batch
• Third-party analytical verification available upon request
• Stability data documented for recommended storage conditions
• Batch-specific QC results traceable by lot number

Research Considerations

Experimental Design Factors:

Researchers should consider several factors when designing Adamax experiments:

1. Administration Route: Intranasal delivery demonstrates effective CNS penetration in research models and may be preferred for brain-focused studies. Systemic routes also show efficacy but may require higher concentrations.

2. Concentration Selection: Determine appropriate concentrations based on research objectives. In vitro studies typically employ nM to μM ranges, while in vivo administration varies by model and route.

3. Temporal Considerations: Adamax’s neuroprotective effects may be both preventative and therapeutic. Timing relative to injury/insult significantly impacts outcomes.

4. Model Selection: Choose appropriate disease models, injury paradigms, or developmental systems based on specific research questions.

5. Endpoint Assessment: Multiple endpoints may be necessary to capture Adamax’s diverse effects: molecular (microtubule stability, tau phosphorylation), cellular (neuronal survival, neurite outgrowth), and functional (cognitive performance, motor function).

Mechanism Investigation:

Adamax’s mechanisms of action involve multiple converging pathways:

• Microtubule stabilization through enhanced tubulin polymerization or MAP interaction
• Tau protein phosphorylation modulation and aggregation prevention
• Activation of survival signaling pathways (PI3K/Akt, ERK/MAPK)
• Regulation of autophagy and protein clearance mechanisms
• Modulation of inflammatory responses and oxidative stress pathways
• Enhancement of neurotrophic factor expression (BDNF, GDNF)

Multi-level experimental approaches combining molecular, cellular, and behavioral assays provide comprehensive mechanistic insights into Adamax’s neuroprotective actions.

Compliance and Safety Information

Regulatory Status:
Adamax is provided as a research chemical for in-vitro laboratory studies and preclinical research only. This product has not been approved by the FDA for human therapeutic use, dietary supplementation, or medical applications. Note: Clinical trials have been conducted under investigational new drug protocols, but this research product is for laboratory use only.

Intended Use:

• In-vitro cell culture studies (neuronal cultures, cell lines)
• In-vivo preclinical research in approved animal models
• Laboratory investigation of biological mechanisms
• Academic and institutional research applications

NOT Intended For:

• Human consumption or administration
• Therapeutic treatment or diagnosis
• Dietary supplementation
• Veterinary therapeutic applications without appropriate oversight

Safety Protocols:
Researchers should follow standard laboratory safety practices when handling Adamax:

• Use appropriate personal protective equipment (lab coat, gloves, safety glasses)
• Handle in well-ventilated areas or fume hood
• Follow institutional biosafety guidelines
• Dispose of waste according to local regulations for biological/chemical waste
• Consult material safety data sheet (MSDS) for additional safety information

—